Monoclonal antibodies have been shown to prevent serious illness in patients who seek treatment within ten days of contracting the virus. Sotrovimab, an FDA EUA approved treatment, is available at Innovative Care and can be scheduled online.
Patients are categorized into one of four risk groups based on their risk of severe illness. Patients in tier 1 and tier 2 are prioritized, but individuals in tiers 3, and 4 will be treated if/when there is excess medication available. We are currently seeing patients in all tier groups. Treatment tiers as identified by IDPH, based on the NIH guidelines, can be found here.
Patients are evaluated by a medical provider to determine if they qualify and to assess their risk of severe illness from COVID-19. If treatment is recommended and agreed upon by both parties, the patient will receive treatment during their visit.
Sotrovimab monoclonal antibodies are administered intravenously. The IV infusion takes 20 to 30 minutes, during which time a patient can relax in one of our recliner chairs. Patients are observed for one-hour following treatment.
Sotrovimab is the only monoclonal antibody that has shown to be effective in treating the Omicron COVID-19 variant. This monoclonal antibody treatment is FDA EUA approved for use in patients who qualify.
Patients who test positive for COVID-19 can make an appointment to be evaluated for treatment online. Treatment must be administered within 10 days of your symptom onset or positive test. For more information or to schedule an appointment, visit Innovative Care online.
Book your appointment today to experience what everyday healthcare should be.